



## Press release

### Invitation to presentation of BioArctic's first quarter report for January – March 2026 on May 20 at 9:30 a.m. CET

**Stockholm, Sweden, May 13, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's first quarter report for January – March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET.**

In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on May 20, at 9:30 a.m. CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the first quarter report, followed by a Q&A session.

If you wish to participate via the webcast, please use the link below, where you will be able to submit written questions.

**Webcast:** <https://bioarctic.events.inderes.com/q1-report-2026/register>

If you wish to ask questions verbally during the presentation, please participate via the teleconference and register using the link below. After registration, you will receive the phone numbers and a conference ID to access the call.

**Teleconference:** <https://events.inderes.com/bioarctic/q1-report-2026/dial-in>

The webcast will also be available on demand on BioArctic's corporate website after the presentation: <https://www.bioarctic.com/en/investors/financial-reports-and-presentations/>

---

**For more information, please contact:**

Anders Martin-Löf, CFO

Phone: +46 70 683 79 77

E-mail: [Anders.martin-lof@bioarctic.com](mailto:Anders.martin-lof@bioarctic.com)

Oskar Bosson

Phone: +46 704 107 180

E-mail: [Oskar.Bosson@bioarctic.com](mailto:Oskar.Bosson@bioarctic.com)

*This information was submitted for publication at 08:30 a.m. CET on May 13, 2026.*

**About BioArctic AB**

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit [www.bioarctic.com](http://www.bioarctic.com).